Literature DB >> 3316505

Double-blind controlled trial of azathioprine in the treatment of multiple sclerosis.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3316505      PMCID： PMC1032473          DOI： 10.1136/jnnp.50.10.1387

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  4 in total

1.  Long-term treatment of multiple sclerosis with azathioprine.

Authors:  W R Swinburn; L A Liversedge
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-02       Impact factor: 10.154

2.  Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

Authors:  S L Hauser; D M Dawson; J R Lehrich; M F Beal; S V Kevy; R D Propper; J A Mills; H L Weiner
Journal:  N Engl J Med       Date:  1983-01-27       Impact factor: 91.245

3.  Azathioprine in treatment of multiple sclerosis. Final results of a 41/2-year controlled study of its effectiveness covering 115 patients.

Authors:  U Patzold; H Hecker; P Pocklington
Journal:  J Neurol Sci       Date:  1982-06       Impact factor: 3.181

4.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910
  4 in total
  1 in total

Review 1.  Azathioprine for multiple sclerosis.

Authors:  I Casetta; G Iuliano; G Filippini
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.